stoxline Quote Chart Rank Option Currency Glossary
  
SpringWorks Therapeutics, Inc. (SWTX)
46.99  0.01 (0.02%)    07-01 16:00
Open: 46.99
High: 46.99
Volume: 5,010,844
  
Pre. Close: 46.99
Low: 46.99
Market Cap: 3,541(M)
Technical analysis
2025-07-18 4:44:54 PM
Short term     
Mid term     
Targets 6-month :  54.91 1-year :  64.14
Resists First :  47.02 Second :  54.91
Pivot price 46.9
Supports First :  46.71 Second :  46.52
MAs MA(5) :  46.98 MA(20) :  46.86
MA(100) :  47.22 MA(250) :  40.67
MACD MACD :  0.2 Signal :  0.3
%K %D K(14,3) :  90.3 D(3) :  89.6
RSI RSI(14): 63.7
52-week High :  62 Low :  28.2
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ SWTX ] has closed below upper band by 27.5%. Bollinger Bands are 96.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 47.03 - 47.26 47.26 - 47.46
Low: 46.43 - 46.7 46.7 - 46.93
Close: 46.59 - 47 47 - 47.36
Company Description

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Headline News

Thu, 10 Jul 2025
Principal Financial Group Inc. Decreases Stock Position in SpringWorks Therapeutics (NASDAQ:SWTX) - MarketBeat

Tue, 01 Jul 2025
SpringWorks Therapeutics, Inc.(NasdaqGS: SWTX) dropped from S&P TMI Index - MarketScreener

Thu, 26 Jun 2025
SpringWorks Merger with Merck Approved by Shareholders - TipRanks

Wed, 30 Apr 2025
Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks - Reuters

Mon, 28 Apr 2025
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks - GlobeNewswire

Mon, 28 Apr 2025
Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B - Investopedia

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 75 (M)
Shares Float 74 (M)
Held by Insiders 1.2 (%)
Held by Institutions 87.4 (%)
Shares Short 6,380 (K)
Shares Short P.Month 5,960 (K)
Stock Financials
EPS -3.42
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.57
Profit Margin -115.6 %
Operating Margin -164.1 %
Return on Assets (ttm) -28.5 %
Return on Equity (ttm) -51.6 %
Qtrly Rev. Growth 133.6 %
Gross Profit (p.s.) 2.71
Sales Per Share 2.91
EBITDA (p.s.) -3.47
Qtrly Earnings Growth 0 %
Operating Cash Flow -165 (M)
Levered Free Cash Flow -94 (M)
Stock Valuations
PE Ratio -13.79
PEG Ratio 0
Price to Book value 8.43
Price to Sales 16.11
Price to Cash Flow -21.41
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android